Product Elements:
Bisoprolol fumarate bisoprolol fumarate bisoprolol fumarate bisoprolol aluminum oxide anhydrous dibasic calcium phosphate butylated hydroxyanisole crospovidone (12 mpa.s at 5%) d&c yellow no. 10 aluminum lake fd&c red no. 40 hypromellose 2910 (6 mpa.s) magnesium stearate microcrystalline cellulose polyethylene glycol 6000 silicon dioxide titanium dioxide light pink to pink 111 bisoprolol fumarate bisoprolol fumarate bisoprolol fumarate bisoprolol anhydrous dibasic calcium phosphate butylated hydroxyanisole crospovidone (12 mpa.s at 5%) hypromellose 2910 (6 mpa.s) magnesium stearate microcrystalline cellulose polyethylene glycol 6000 silicon dioxide titanium dioxide white to off white colored with occasional greyish 112
Indications and Usage:
Indications and usage bisoprolol fumarate tablets are indicated in the management of hypertension. it may be used alone or in combination with other antihypertensive agents.
Warnings:
Warnings cardiac failure sympathetic stimulation is a vital component supporting circulatory function in the setting of congestive heart failure and beta-blockade may result in further depression of myocardial contractility and precipitate more severe failure. in general, beta-blocking agents should be avoided in patients with overt congestive failure. however, in some patients with compensated cardiac failure it may be necessary to utilize them. in such a situation, they must be used cautiously. in patients without a history of cardiac failure continued depression of the myocardium with beta-blockers can, in some patients, precipitate cardiac failure. at the first signs or symptoms of heart failure, discontinuation of bisoprolol fumarate should be considered. in some cases, beta-blocker therapy can be continued while heart failure is treated with other drugs. abrupt cessation of therapy exacerbation of angina pectoris and, in some instances, myocardial infarction or ventricular arrhyt
Read more...hmia, have been observed in patients with coronary artery disease following abrupt cessation of therapy with beta-blockers. such patients should, therefore, be cautioned against interruption or discontinuation of therapy without the physician's advice. even in patients without overt coronary artery disease, it may be advisable to taper therapy with bisoprolol fumarate over approximately one week with the patient under careful observation. if withdrawal symptoms occur, bisoprolol fumarate therapy should be reinstituted, at least temporarily. peripheral vascular disease beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. caution should be exercised in such individuals. bronchospastic disease patients with bronchospastic disease should, in general, not receive beta-blockers. because of its relative beta 1 -selectivity, however, bisoprolol fumarate may be used with caution in patients with bronchospastic disease who do not respond to or who cannot tolerate other antihypertensive treatment. since beta 1 -selectivity is not absolute, the lowest possible dose of bisoprolol fumarate should be used, with therapy starting at 2.5 mg. a beta 2 agonist (bronchodilator) should be made available. major surgery chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. diabetes and hypoglycemia beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. because of its beta 1 -selectivity, this is less likely with bisoprolol fumarate. however, patients subject to spontaneous hypoglycemia or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. thyrotoxicosis beta-adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia. abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm.
Dosage and Administration:
Dosage and administration the dose of bisoprolol fumarate tablets, usp must be individualized to the needs of the patient. the usual starting dose is 5 mg once daily. in some patients, 2.5 mg may be an appropriate starting dose (see bronchospastic disease in warnings ). if the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily. patients with renal or hepatic impairment in patients with hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance less than 40 ml/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration. since limited data suggest that bisoprolol fumarate is not dialyzable, drug replacement is not necessary in patients undergoing dialysis. geriatric patients it is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and geriatric use in precautions ). pediatric patients t
Read more...here is no pediatric experience with bisoprolol fumarate.
Contraindications:
Contraindications bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree av block and marked sinus bradycardia.
Adverse Reactions:
Adverse reactions safety data are available in more than 30,000 patients or volunteers. frequency estimates and rates of withdrawal of therapy for adverse events were derived from two u.s. placebo-controlled studies. in study a, doses of 5 mg, 10 mg and 20 mg bisoprolol fumarate were administered for 4 weeks. in study b, doses of 2.5 mg, 10 mg and 40 mg of bisoprolol fumarate were administered for 12 weeks. a total of 273 patients were treated with 5 mg to 20 mg of bisoprolol fumarate; 132 received placebo. withdrawal of therapy for adverse events was 3.3% for patients receiving bisoprolol fumarate and 6.8% for patients on placebo. withdrawals were less than 1% for either bradycardia or fatigue/lack of energy. the following table presents adverse experiences, whether or not considered drug related, reported in at least 1% of patients in these studies, for all patients studied in placebo-controlled clinical trials (2.5 mg to 40 mg), as well as for a subgroup that was treated with doses
Read more...within the recommended dosage range (5 mg to 20 mg). of the adverse events listed in the table, bradycardia, diarrhea, asthenia, fatigue and sinusitis appear to be dose related. a percentage of patients with event body system/adverse experience all adverse experiences (% a ) bisoprolol fumarate placebo (n=132) 5 mg to 20 mg (n=273) 2.5 mg to 40 mg (n=404) % % % skin increased sweating 1.5 0.7 1 musculoskeletal arthralgia 2.3 2.2 2.7 central nervous system dizziness 3.8 2.9 3.5 headache 11.4 8.8 10.9 hypoaesthesia 0.8 1.1 1.5 autonomic nervous system dry mouth 1.5 0.7 1.3 heart rate/rhythm bradycardia 0 0.4 0.5 psychiatric vivid dreams 0 0 0 insomnia 2.3 1.5 2.5 depression 0.8 0 0.2 gastrointestinal diarrhea 1.5 2.6 3.5 nausea 1.5 1.5 2.2 vomiting 0 1.1 1.5 respiratory bronchospasm 0 0 0 cough 4.5 2.6 2.5 dyspnea 0.8 1.1 1.5 pharyngitis 2.3 2.2 2.2 rhinitis 3 2.9 4 sinusitis 1.5 2.2 2.2 uri 3.8 4.8 5 body as a whole asthenia 0 0.4 1.5 chest pain 0.8 1.1 1.5 fatigue 1.5 6.6 8.2 edema (peripheral) 3.8 3.7 3 the following is a comprehensive list of adverse experiences reported with bisoprolol fumarate in worldwide studies or in postmarketing experience (in italics): central nervous system dizziness, unsteadiness , vertigo, syncope, headache, paresthesia, hypoesthesia, hyperesthesia, somnolence, sleep disturbances , anxiety/restlessness, decreased concentration/memory. autonomic nervous system dry mouth. cardiovascular bradycardia, palpitations and other rhythm disturbances, cold extremities, claudication, hypotension, orthostatic hypotension, chest pain, congestive heart failure, dyspnea on exertion. psychiatric vivid dreams, insomnia, depression. gastrointestinal gastric/epigastric/abdominal pain, gastritis, dyspepsia, nausea, vomiting, diarrhea, constipation, peptic ulcer. musculoskeletal muscle/joint pain, arthralgia , back/neck pain, muscle cramps, twitching/tremor. skin rash, acne, eczema, psoriasis , skin irritation, pruritus, flushing, sweating, alopecia, dermatitis, angioedema, exfoliative dermatitis , cutaneous vasculitis. special senses visual disturbances, ocular pain/pressure, abnormal lacrimation, tinnitus, decreased hearing , earache, taste abnormalities. metabolic gout. respiratory asthma/bronchospasm, bronchitis, coughing, dyspnea, pharyngitis, rhinitis, sinusitis, uri. genitourinary decreased libido/impotence, peyronie's disease , cystitis, renal colic, polyuria. hematologic purpura. general fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. in addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of bisoprolol fumarate: central nervous system reversible mental depression progressing to catatonia, hallucinations, an acute reversible syndrome characterized by disorientation to time and place, emotional lability, slightly clouded sensorium. allergic fever, combined with aching and sore throat, laryngospasm, respiratory distress. hematologic agranulocytosis, thrombocytopenia, thrombocytopenic purpura. gastrointestinal mesenteric arterial thrombosis, ischemic colitis. miscellaneous the oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with bisoprolol fumarate during investigational use or extensive foreign marketing experience.
Adverse Reactions Table:
| a percentage of patients with event |
| Body System/Adverse Experience | All Adverse Experiences (%a) Bisoprolol Fumarate |
| Placebo (n=132) | 5 mg to 20 mg (n=273) | 2.5 mg to 40 mg (n=404) |
| % | % | % |
| Skin | | | |
| increased sweating | 1.5 | 0.7 | 1 |
| Musculoskeletal | | | |
| arthralgia | 2.3 | 2.2 | 2.7 |
| Central Nervous System | | | |
| dizziness | 3.8 | 2.9 | 3.5 |
| headache | 11.4 | 8.8 | 10.9 |
| hypoaesthesia | 0.8 | 1.1 | 1.5 |
| Autonomic Nervous System | | | |
| dry mouth | 1.5 | 0.7 | 1.3 |
| Heart Rate/Rhythm | | | |
| bradycardia | 0 | 0.4 | 0.5 |
| Psychiatric | | | |
| vivid dreams | 0 | 0 | 0 |
| insomnia | 2.3 | 1.5 | 2.5 |
| depression | 0.8 | 0 | 0.2 |
| Gastrointestinal | | | |
| diarrhea | 1.5 | 2.6 | 3.5 |
| nausea | 1.5 | 1.5 | 2.2 |
| vomiting | 0 | 1.1 | 1.5 |
| Respiratory | | | |
| bronchospasm | 0 | 0 | 0 |
| cough | 4.5 | 2.6 | 2.5 |
| dyspnea | 0.8 | 1.1 | 1.5 |
| pharyngitis | 2.3 | 2.2 | 2.2 |
| rhinitis | 3 | 2.9 | 4 |
| sinusitis | 1.5 | 2.2 | 2.2 |
| URI | 3.8 | 4.8 | 5 |
| Body as a Whole | | | |
| asthenia | 0 | 0.4 | 1.5 |
| chest pain | 0.8 | 1.1 | 1.5 |
| fatigue | 1.5 | 6.6 | 8.2 |
| edema (peripheral) | 3.8 | 3.7 | 3 |
Overdosage:
Overdosage the most common signs expected with overdosage of a beta-blocker are bradycardia, hypotension, congestive heart failure, bronchospasm and hypoglycemia. to date, a few cases of overdose (maximum: 2,000 mg) with bisoprolol fumarate have been reported. bradycardia and/or hypotension were noted. sympathomimetic agents were given in some cases and all patients recovered. in general, if overdose occurs, bisoprolol fumarate therapy should be stopped and supportive and symptomatic treatment should be provided. limited data suggest that bisoprolol fumarate is not dialyzable. based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures should be considered when clinically warranted: bradycardia administer iv atropine. if the response is inadequate, isoproterenol or another agent with positive chronotropic properties may be given cautiously. under some circumstances, transvenous pacemaker insertion may be necessary. hypotension iv fluids and vasopressors should be administered. intravenous glucagon may be useful. heart block (second or third degree) patients should be carefully monitored and treated with isoproterenol infusion or transvenous cardiac pacemaker insertion, as appropriate. congestive heart failure initiate conventional therapy (i.e., digitalis, diuretics, inotropic agents, vasodilating agents). bronchospasm administer bronchodilator therapy such as isoproterenol and/or aminophylline. hypoglycemia administer iv glucose.
Description:
Description bisoprolol fumarate, usp is a synthetic, beta 1 -selective (cardioselective) adrenoceptor blocking agent. the chemical name for bisoprolol fumarate is (±)-1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol( e )-2-butenedioate (2:1) (salt). it possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. the s(-) enantiomer is responsible for most of the beta-blocking activity. its molecular formula is (c 18 h 31 no 4 ) 2 â¢c 4 h 4 o 4 and its structure is: bisoprolol fumarate has a molecular weight of 766.96. it is a white crystalline powder which is approximately equally hydrophilic and lipophilic and is very soluble in water and methanol; freely soluble in chloroform, glacial acetic acid and ethanol; slightly soluble in ethyl acetate and acetone. bisoprolol fumarate tablets, usp is available as 5 mg and 10 mg tablets for oral administration. each tablet contains following inactive ingredients: butylated hydroxyanisole, colloidal silicon dioxide, crospovidone, dibasic calcium phosphate anhydrous, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide. additionally, each 5 mg tablet contains d&c yellow #10 aluminum lake and fd&c red #40 aluminum lake. fda approved dissolution test specifications differ from usp. image
Clinical Pharmacology:
Clinical pharmacology bisoprolol fumarate is a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. cardioselectivity is not absolute, however and at higher doses (⥠20 mg) bisoprolol fumarate also inhibits beta 2 -adrenoceptors, chiefly located in the bronchial and vascular musculature; to retain selectivity it is therefore important to use the lowest effective dose. pharmacokinetics and metabolism the absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%. absorption is not affected by the presence of food. the first pass metabolism of bisoprolol fumarate is about 20%. binding to serum proteins is approximately 30%. peak plasma concentrations occur within 2 hours to 4 hours of dosing with 5 mg to 20 mg and mean peak values range from 16 ng/ml at 5 mg to 70 ng/ml at 20 mg. once daily dosing with bisoprolol fumarate resul
Read more...ts in less than twofold intersubject variation in peak plasma levels. the plasma elimination half-life is 9 hours to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population. steady state is attained within 5 days of once daily dosing. in both young and elderly populations, plasma accumulation is low; the accumulation factor ranges from 1.1 to 1.3 and is what would be expected from the first order kinetics and once daily dosing. plasma concentrations are proportional to the administered dose in the range of 5 mg to 20 mg. pharmacokinetic characteristics of the two enantiomers are similar. bisoprolol fumarate is eliminated equally by renal and non-renal pathways with about 50% of the dose appearing unchanged in the urine and the remainder appearing in the form of inactive metabolites. in humans, the known metabolites are labile or have no known pharmacologic activity. less than 2% of the dose is excreted in the feces. bisoprolol fumarate is not metabolized by cytochrome p450 ii d6 (debrisoquin hydroxylase). in subjects with creatinine clearance less than 40 ml/min, the plasma half-life is increased approximately threefold compared to healthy subjects. in patients with cirrhosis of the liver, the elimination of bisoprolol fumarate is more variable in rate and significantly slower than that in healthy subjects, with plasma half-life ranging from 8.3 hours to 21.7 hours. pharmacodynamics the most prominent effect of bisoprolol fumarate is the negative chronotropic effect, resulting in a reduction in resting and exercise heart rate. there is a fall in resting and exercise cardiac output with little observed change in stroke volume and only a small increase in right atrial pressure or pulmonary capillary wedge pressure at rest or during exercise. findings in short-term clinical hemodynamics studies with bisoprolol fumarate are similar to those observed with other beta-blocking agents. the mechanism of action of its antihypertensive effects has not been completely established. factors which may be involved include: decreased cardiac output, inhibition of renin release by the kidneys, diminution of tonic sympathetic outflow from the vasomotor centers in the brain. in normal volunteers, bisoprolol fumarate therapy resulted in a reduction of exercise- and isoproterenol-induced tachycardia. the maximal effect occurred within 1 hour to 4 hours post-dosing. effects persisted for 24 hours at doses equal to or greater than 5 mg. electrophysiology studies in man have demonstrated that bisoprolol fumarate significantly decreases heart rate, increases sinus node recovery time, prolongs av node refractory periods and, with rapid atrial stimulation, prolongs av nodal conduction. beta 1 -selectivity of bisoprolol fumarate has been demonstrated in both animal and human studies. no effects at therapeutic doses on beta 2 -adrenoceptor density have been observed. pulmonary function studies have been conducted in healthy volunteers, asthmatics and patients with chronic obstructive pulmonary disease (copd). doses of bisoprolol fumarate ranged from 5 mg to 60 mg, atenolol from 50 mg to 200 mg, metoprolol from 100 mg to 200 mg and propranolol from 40 mg to 80 mg. in some studies, slight, asymptomatic increases in airways resistance (awr) and decreases in forced expiratory volume (fev 1 ) were observed with doses of bisoprolol fumarate 20 mg and higher, similar to the small increases in awr also noted with the other cardioselective beta-blockers. the changes induced by beta-blockade with all agents were reversed by bronchodilator therapy. bisoprolol fumarate had minimal effect on serum lipids during antihypertensive studies. in u.s. placebo-controlled trials, changes in total cholesterol averaged +0.8% for bisoprolol fumarate-treated patients and +0.7% for placebo. changes in triglycerides averaged +19% for bisoprolol fumarate-treated patients and +17% for placebo. bisoprolol fumarate has also been given concomitantly with thiazide diuretics. even very low doses of hydrochlorothiazide (6.25 mg) were found to be additive with bisoprolol fumarate in lowering blood pressure in patients with mild-to-moderate hypertension.
Pharmacodynamics:
Pharmacodynamics the most prominent effect of bisoprolol fumarate is the negative chronotropic effect, resulting in a reduction in resting and exercise heart rate. there is a fall in resting and exercise cardiac output with little observed change in stroke volume and only a small increase in right atrial pressure or pulmonary capillary wedge pressure at rest or during exercise. findings in short-term clinical hemodynamics studies with bisoprolol fumarate are similar to those observed with other beta-blocking agents. the mechanism of action of its antihypertensive effects has not been completely established. factors which may be involved include: decreased cardiac output, inhibition of renin release by the kidneys, diminution of tonic sympathetic outflow from the vasomotor centers in the brain. in normal volunteers, bisoprolol fumarate therapy resulted in a reduction of exercise- and isoproterenol-induced tachycardia. the maximal effect occurred within 1 hour to 4 hours post-dosing. effects persisted for 24 hours at doses equal to or greater than 5 mg. electrophysiology studies in man have demonstrated that bisoprolol fumarate significantly decreases heart rate, increases sinus node recovery time, prolongs av node refractory periods and, with rapid atrial stimulation, prolongs av nodal conduction. beta 1 -selectivity of bisoprolol fumarate has been demonstrated in both animal and human studies. no effects at therapeutic doses on beta 2 -adrenoceptor density have been observed. pulmonary function studies have been conducted in healthy volunteers, asthmatics and patients with chronic obstructive pulmonary disease (copd). doses of bisoprolol fumarate ranged from 5 mg to 60 mg, atenolol from 50 mg to 200 mg, metoprolol from 100 mg to 200 mg and propranolol from 40 mg to 80 mg. in some studies, slight, asymptomatic increases in airways resistance (awr) and decreases in forced expiratory volume (fev 1 ) were observed with doses of bisoprolol fumarate 20 mg and higher, similar to the small increases in awr also noted with the other cardioselective beta-blockers. the changes induced by beta-blockade with all agents were reversed by bronchodilator therapy. bisoprolol fumarate had minimal effect on serum lipids during antihypertensive studies. in u.s. placebo-controlled trials, changes in total cholesterol averaged +0.8% for bisoprolol fumarate-treated patients and +0.7% for placebo. changes in triglycerides averaged +19% for bisoprolol fumarate-treated patients and +17% for placebo. bisoprolol fumarate has also been given concomitantly with thiazide diuretics. even very low doses of hydrochlorothiazide (6.25 mg) were found to be additive with bisoprolol fumarate in lowering blood pressure in patients with mild-to-moderate hypertension.
Clinical Studies:
Clinical studies in two randomized double-blind placebo-controlled trials conducted in the u.s., reductions in systolic and diastolic blood pressure and heart rate 24 hours after dosing in patients with mild-to-moderate hypertension are shown below. in both studies, mean systolic/diastolic blood pressures at baseline were approximately 150/100 mm hg and mean heart rate was 76 bpm. drug effect is calculated by subtracting the placebo effect from the overall change in blood pressure and heart rate. a observed total change from baseline minus placebo. sitting systolic/diastolic pressure (bp) and heart rate (hr) mean decrease (d) after 3 to 4 weeks study a bisoprolol fumarate placebo 5 mg 10 mg 20 mg n= 61 61 61 61 total Îbp (mm hg) 5.4/3.2 10.4/8 11.2/10.9 12.8/11.9 drug effect a - 5/4.8 5.8/7.7 7.4/8.7 total Îhr (bpm) 0.5 7.2 8.7 11.3 drug effect a - 6.7 8.2 10.8 study b bisoprolol fumarate placebo 2.5 mg 10 mg n= 56 59 62 total Îbp (mm hg) 3/3.7 7.6/8.1 13.5/11.2 drug effect a
Read more...- 4.6/4.4 10.5/7.5 total Îhr (bpm) 1.6 3.8 10.7 drug effect a - 2.2 9.1 blood pressure responses were seen within one week of treatment and changed little thereafter. they were sustained for 12 weeks and for over a year in studies of longer duration. blood pressure returned to baseline when bisoprolol fumarate was tapered over two weeks in a long-term study. overall, significantly greater blood pressure reductions were observed on bisoprolol fumarate than on placebo regardless of race, age or gender. there were no significant differences in response between black and nonblack patients.
How Supplied:
How supplied bisoprolol fumarate tablets, usp is supplied as 5 mg and 10 mg tablets. bisoprolol fumarate tablets, usp 5 mg are light pink to pink colored, round shaped, film-coated tablets, debossed with "111" on one side and scored on the other side, supplied as follows: ndc 72578-111-06 in bottles of 30 tablets with child-resistant closure. ndc 72578-111-01 in bottles of 100 tablets with child-resistant closure. bisoprolol fumarate tablets, usp 10 mg are white to off white colored with occasional greyish to black speckles, round shaped, film-coated tablets, debossed with "112" on one side and plain on the other side, supplied as follows: ndc 72578-112-06 in bottles of 30 tablets with child-resistant closure. ndc 72578-112-01 in bottles of 100 tablets with child-resistant closure. store at 20°c to 25°c (68°f to 77°f); excursions permitted between 15°c to 30°c (59°f to 86°f). [see usp controlled room temperature.] protect from moisture. dispense in a tight, ligh
Read more...t-resistant container. call your doctor for medical advice about side effects. you may report side effects to viona pharmaceuticals inc. at 1-888-304-5011 or fda at 1-800-fda-1088.
Package Label Principal Display Panel:
Package label.principal display panel ndc 72578-111-06 bisoprolol fumarate tablets usp, 5 mg 30 tablets unit-of-use rx only viona ndc 72578-112-06 bisoprolol fumarate tablets usp, 10 mg 30 tablets unit-of-use rx only viona 5 mg 10 mg